nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,intervention_type,intervention_name,description,n.x,status,facility_name,city,state,zip,country,n.y
NCT04244591,"ClinicalTrials.gov processed this data on February 25, 2020",2020-01-23,NA,NA,2020-02-12,2020-01-25,2020-01-28,Actual,NA,NA,NA,NA,NA,NA,2020-02-12,2020-02-13,Actual,"January 26, 2020",Actual,2020-01-26,February 2020,2020-02-29,"December 25, 2020",Anticipated,2020-12-25,"April 25, 2020",Anticipated,2020-04-25,NA,Interventional,Steroids-SARI,,Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure,"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by Noval Coronovirus 2019-nCoV: a Prospective, Randomized Controlled Trial",Recruiting,NA,Phase 2/Phase 3,80,Anticipated,Peking Union Medical College Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-02-25T23:43:27Z,2020-02-25T23:43:27Z,Drug|Other,methylprednisolone therapy|Standard care,Methylprednisolone 40 mg q12h for 5 days|Standard care,2,Recruiting,"Medical ICU,Peking Union Medical College Hospital",Beijing,Beijing,010,China,1
NCT04252118,"ClinicalTrials.gov processed this data on March 06, 2020",2020-01-27,NA,NA,2020-02-25,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-02-25,2020-02-26,Actual,"January 27, 2020",Actual,2020-01-27,February 2020,2020-02-29,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus,Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,20,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-08T05:21:43Z,2020-03-08T05:21:43Z,Biological,MSCs,"3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6).",1,Recruiting,Beijing 302 Military Hospital of China,Beijing,,100039,China,1
NCT04251871,"ClinicalTrials.gov processed this data on February 25, 2020",2020-01-28,NA,NA,2020-01-30,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-01-30,2020-02-05,Actual,"January 22, 2020",Actual,2020-01-22,January 2020,2020-01-31,"January 22, 2021",Anticipated,2021-01-22,"January 22, 2021",Anticipated,2021-01-22,NA,Interventional,NA,,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection,"Effects of Traditional Chinese Medicines (TCMs) on Patients With 2019-nCoV Infection: A Perspective, Open-labeled, Randomized, Controlled Trial",Recruiting,NA,N/A,150,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-02-25T23:42:38Z,2020-02-25T23:42:38Z,Drug|Drug,"Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days.|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.",2,Recruiting,"The Fifth Medical Center, General Hospital of PLA",Beijing,Beijing,100039,China,1
NCT04252274,"ClinicalTrials.gov processed this data on March 13, 2020",2020-01-29,NA,NA,2020-03-03,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-04,Actual,"January 30, 2020",Actual,2020-01-30,March 2020,2020-03-31,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,DACO-nCoV,,Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV,Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV,Recruiting,NA,Phase 3,30,Anticipated,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-15T09:22:12Z,2020-03-15T09:22:12Z,Drug,Darunavir and Cobicistat,"Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments",1,Recruiting|Recruiting,Shanghai Public Health Clinical Center|Shanghai Public Health Clinical Center,Shanghai|Shanghai,Shanghai|Shanghai,201508|,China|China,2
NCT04252885,"ClinicalTrials.gov processed this data on February 25, 2020",2020-01-30,NA,NA,2020-01-31,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-01-31,2020-02-05,Actual,"January 28, 2020",Anticipated,2020-01-28,January 2020,2020-01-31,"July 31, 2020",Anticipated,2020-07-31,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,ELACOI,,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Recruiting,NA,Phase 4,125,Anticipated,Guangzhou 8th People's Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-02-25T23:42:31Z,2020-02-25T23:42:31Z,Drug|Drug,Lopinavir and Ritonavir Tablets|Arbidol,As indicated in arm/group descriptions|As indicated in arm/group descriptions,2,Recruiting,Guangzhou Eighth People's Hospital,Guangzhou,Guangdong,510060,China,1
NCT04251767,"ClinicalTrials.gov processed this data on March 23, 2020",2020-01-30,NA,NA,2020-03-13,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-17,Actual,"February 5, 2020",Anticipated,2020-02-05,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Washed Microbiota Transplantation for Patients With 2019-nCoV Infection,"Washed Microbiota Transplantation for Patients With 2019-nCoV Infection: a Randomized, Double-blind, Placebo-controlled Study",Withdrawn,NA,N/A,0,Actual,The Second Hospital of Nanjing Medical University,,2,NA,Follow new disciplines on disease control from government,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-24T08:58:00Z,2020-03-24T08:58:00Z,Other|Other,washed microbiota transplantation|placebo,"Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.
Dose and frequency: 5u, once.|Placebo (edible suspension of the same color as the washed microbiota suspensionï¼Œ5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
Dose and frequency: 5u, once.",2,,"Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University",Nanjing,Jiangsu,210011,China,1
NCT04257656,"ClinicalTrials.gov processed this data on March 05, 2020",2020-01-31,NA,NA,2020-02-20,2020-02-03,2020-02-06,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-24,Actual,"February 6, 2020",Actual,2020-02-06,February 2020,2020-02-29,"May 1, 2020",Anticipated,2020-05-01,"April 3, 2020",Anticipated,2020-04-03,NA,Interventional,NA,,Severe 2019-nCoV Remdesivir RCT,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe 2019-nCoVRespiratory Disease.",Recruiting,NA,Phase 3,453,Anticipated,Capital Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-06T05:32:37Z,2020-03-06T05:32:37Z,Drug|Drug,Remdesivir|Remdesivir placebo,"RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",2,Recruiting,Bin Cao,Beijing,Beijing,100029,China,1
NCT04252664,"ClinicalTrials.gov processed this data on March 05, 2020",2020-01-31,NA,NA,2020-02-20,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-24,Actual,"February 12, 2020",Actual,2020-02-12,February 2020,2020-02-29,"April 27, 2020",Anticipated,2020-04-27,"April 10, 2020",Anticipated,2020-04-10,NA,Interventional,NA,,Mild/Moderate 2019-nCoV Remdesivir RCT,"A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate 2019-nCoV Respiratory Disease.",Recruiting,NA,Phase 3,308,Anticipated,Capital Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-06T05:32:54Z,2020-03-06T05:32:54Z,Drug|Drug,Remdesivir|Remdesivir placebo,"RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",2,Recruiting,Jin Yin-tan hospital,Wu Han,Hubei,100013,China,1
NCT04263402,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-07,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-24T08:57:41Z,2020-03-24T08:57:41Z,Drug|Drug,Methylprednisolone|Methylprednisolone,"Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(<40mg/d intravenous drip for 7 days).|Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40~80mg/d intravenous drip for 7 days).",2,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04255017,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,400,Anticipated,Tongji Hospital,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-24T08:57:55Z,2020-03-24T08:57:55Z,Drug|Drug|Drug,Abidol hydrochloride|Oseltamivir|Lopinavir/ritonavir,"Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.|Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.|Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.",3,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04254874,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-24T08:57:55Z,2020-03-24T08:57:55Z,Drug|Drug,Abidol hydrochloride|Abidol Hydrochloride combined with Interferon atomization,"0.2g once, 3 times a day,two weeks|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-Î±-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks",2,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04264533,"ClinicalTrials.gov processed this data on March 19, 2020",2020-02-04,NA,NA,2020-03-06,2020-02-08,2020-02-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-10,Actual,"February 14, 2020",Actual,2020-02-14,February 2020,2020-02-29,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial,Recruiting,NA,Phase 2,140,Anticipated,Zhongnan Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-20T09:20:07Z,2020-03-20T09:20:07Z,Drug|Drug,VC|Sterile Water for Injection,12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.|50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.,2,Recruiting,Zhongnan Hospital of Wuhan University,Wuhan,Hubei,430000,China,1
NCT04261270,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-04,NA,NA,2020-03-14,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia",Recruiting,NA,Phase 3,60,Anticipated,Tongji Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-24T08:57:44Z,2020-03-24T08:57:44Z,Drug|Drug|Drug,ASC09F+Oseltamivir|Ritonavir+Oseltamivir|Oseltamivir,"ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day|75mg ,once a day",3,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04261517,"ClinicalTrials.gov processed this data on March 13, 2020",2020-02-06,NA,NA,2020-03-03,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-04,Actual,"February 6, 2020",Actual,2020-02-06,March 2020,2020-03-31,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ),Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ),Recruiting,NA,Phase 3,30,Anticipated,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-15T09:21:45Z,2020-03-15T09:21:45Z,Drug,Hydroxychloroquine,"Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments",1,Recruiting|Recruiting,Shanghai Public Health Clinical Center|Shanghai Public Health Clinical Center,Shanghai|Shanghai,Shanghai|Shanghai,201508|,China|China,2
NCT04261907,"ClinicalTrials.gov processed this data on February 25, 2020",2020-02-06,NA,NA,2020-02-06,2020-02-06,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-02-06,2020-02-10,Actual,"February 7, 2020",Anticipated,2020-02-07,February 2020,2020-02-29,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection,"A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection",Not yet recruiting,NA,N/A,160,Anticipated,First Affiliated Hospital of Zhejiang University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-02-25T23:41:29Z,2020-02-25T23:41:29Z,Drug|Drug,ASC09/ritonavir group|lopinavir/ritonavir group,"ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment|Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment",2,NA,NA,NA,NA,NA,NA,NA
NCT04260594,"ClinicalTrials.gov processed this data on February 25, 2020",2020-02-06,NA,NA,2020-02-06,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-02-06,2020-02-07,Actual,"February 7, 2020",Anticipated,2020-02-07,February 2020,2020-02-29,"December 30, 2020",Anticipated,2020-12-30,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus,"Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).",Not yet recruiting,NA,Phase 4,380,Anticipated,Ruijin Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-02-25T23:41:37Z,2020-02-25T23:41:37Z,Drug|Other,Arbidol|basic treatment,"Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days|basic treatment",2,NA,NA,NA,NA,NA,NA,NA
NCT04275245,"ClinicalTrials.gov processed this data on February 28, 2020",2020-02-06,NA,NA,2020-02-16,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-16,2020-02-19,Actual,"February 3, 2020",Actual,2020-02-03,February 2020,2020-02-29,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,"Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Tang-Du Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-01T00:05:12Z,2020-03-01T00:05:12Z,Drug,Meplazumab for Injection,humanized MAb against CD147,1,Recruiting,Tangdu Hospital,Xi'an,Shaanxi,710032,China,1
NCT04269525,"ClinicalTrials.gov processed this data on February 27, 2020",2020-02-07,NA,NA,2020-02-12,2020-02-12,2020-02-13,Actual,NA,NA,NA,NA,NA,NA,2020-02-12,2020-02-17,Actual,"February 6, 2020",Actual,2020-02-06,February 2020,2020-02-29,"September 30, 2020",Anticipated,2020-09-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection,Recruiting,NA,Phase 2,10,Anticipated,Zhongnan Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-02-27T20:36:08Z,2020-02-27T20:36:08Z,Biological,UC-MSCs,"After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.",1,Recruiting,Zhongnan Hospital of Wuhan University,Wuhan,Hubei,430000,China,1
NCT04268537,"ClinicalTrials.gov processed this data on February 25, 2020",2020-02-08,NA,NA,2020-02-12,2020-02-12,2020-02-13,Actual,NA,NA,NA,NA,NA,NA,2020-02-12,2020-02-13,Actual,"February 10, 2020",Anticipated,2020-02-10,February 2020,2020-02-29,"October 31, 2020",Anticipated,2020-10-31,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Immunoregulatory Therapy for 2019-nCoV,Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients,Not yet recruiting,NA,Phase 2,120,Anticipated,"Southeast University, China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-02-25T23:40:46Z,2020-02-25T23:40:46Z,Drug|Drug|Other,PD-1 blocking antibody+standard treatment|Thymosin+standard treatment|standard treatment,"After randomization, PD-1 blocking antibody 200mg iv, one time. Standard treatment is according to the protocol of treatment of 2019-nCoV infection|Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection|Standard treatment is according to the protocol of treatment of 2019-nCoV infection",3,NA,NA,NA,NA,NA,NA,NA
NCT04264858,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-08,NA,NA,2020-03-13,2020-02-08,2020-02-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-17,Actual,"March 17, 2020",Anticipated,2020-03-17,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients,An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients,Not yet recruiting,NA,N/A,10,Anticipated,"Wuhan Union Hospital, China",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-24T08:57:40Z,2020-03-24T08:57:40Z,Drug|Drug,Immunoglobulin of cured patients|Î³-Globulin,"0.2g/kg, ivdrip, once a day, for 3 days|0.2g/kg, ivdrip, once a day, for 3 days",2,,"Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Wuhan,Hubei,430022,China,1
NCT04282902,"ClinicalTrials.gov processed this data on March 06, 2020",2020-02-10,NA,NA,2020-02-21,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"June 1, 2020",Anticipated,2020-06-01,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection",Recruiting,NA,Phase 3,294,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-07T05:29:32Z,2020-03-07T05:29:32Z,Drug,pirfenidone,"Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer",1,Recruiting,Tongji hospital affiliated to huazhong university of science and technology,Wuhan,Hubei,,China,1
NCT04276688,"ClinicalTrials.gov processed this data on March 09, 2020",2020-02-11,NA,NA,2020-02-26,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-26,2020-02-28,Actual,"February 10, 2020",Actual,2020-02-10,February 2020,2020-02-29,"July 31, 2022",Anticipated,2022-07-31,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,NA,,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Recruiting,NA,Phase 2,70,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-10T09:11:56Z,2020-03-10T09:11:56Z,Drug|Drug|Drug,Lopinavir/ritonavir|Ribavirin|Interferon Beta-1B,400mg/100mg twice daily for 14 days|400mg twice daily for 14 days|0.25mg subcutaneous injection alternate day for 3 days,3,Recruiting,"University of Hong Kong, Queen Mary Hospital",Hong Kong,,,Hong Kong,1
NCT04280224,"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-13,NA,NA,2020-02-20,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-21,Actual,"February 20, 2020",Anticipated,2020-02-20,February 2020,2020-02-29,"December 30, 2020",Anticipated,2020-12-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,NK Cells Treatment for Novel Coronavirus Pneumonia,Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,30,Anticipated,Xinxiang medical university,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-03T05:07:25Z,2020-03-03T05:07:25Z,Biological,NK Cells,twice a week of NK cells (0.1-2*10E7 cells/kg body weight),1,Recruiting,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang,Henan,453000,China,1
NCT04275414,"ClinicalTrials.gov processed this data on February 28, 2020",2020-02-14,NA,NA,2020-02-16,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-16,2020-02-19,Actual,February 2020,Anticipated,2020-02-29,February 2020,2020-02-29,May 2020,Anticipated,2020-05-31,April 2020,Anticipated,2020-04-30,NA,Interventional,BEST-CP,,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP),Recruiting,NA,Phase 2/Phase 3,20,Anticipated,Qilu Hospital of Shandong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-01T00:05:05Z,2020-03-01T00:05:05Z,Drug,Bevacizumab Injection,"Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip â‰¥90min",1,Recruiting,Qilu Hospital of Shandong University,Jinan,Shandong,250012,China,1
NCT04273646,"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-14,NA,NA,2020-02-19,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 16, 2020",Anticipated,2020-02-16,February 2020,2020-02-29,"February 15, 2022",Anticipated,2022-02-15,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia,Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia,Not yet recruiting,NA,N/A,48,Anticipated,"Wuhan Union Hospital, China",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-03T05:08:27Z,2020-03-03T05:08:27Z,Biological|Drug,UC-MSCs|Placebo,"4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).|4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).",2,,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Wuhan,Hubei,430000,China,1
NCT04273581,"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-14,NA,NA,2020-02-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 18, 2020",Anticipated,2020-02-18,February 2020,2020-02-29,"May 30, 2020",Anticipated,2020-05-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19,"The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study",Not yet recruiting,NA,Phase 2,40,Anticipated,First Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-03T05:08:27Z,2020-03-03T05:08:27Z,Drug|Drug,placebo|Thalidomide,100mg/dï¼Œqnï¼Œfor 14 days.|100mg/dï¼Œqnï¼Œfor 14 days.,2,NA,NA,NA,NA,NA,NA,NA
NCT04273529,"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-14,NA,NA,2020-02-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 20, 2020",Anticipated,2020-02-20,February 2020,2020-02-29,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia,"The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study",Not yet recruiting,NA,Phase 2,100,Anticipated,First Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-03T05:08:27Z,2020-03-03T05:08:27Z,Drug|Drug,thalidomide|placebo,100mgï¼Œpoï¼Œqnï¼Œfor 14 days.|100mgï¼Œpoï¼Œqnï¼Œfor 14 days.,2,NA,NA,NA,NA,NA,NA,NA
NCT04304313,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-14,NA,NA,2020-03-14,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 9, 2020",Actual,2020-02-09,March 2020,2020-03-31,"November 9, 2020",Anticipated,2020-11-09,"March 1, 2020",Actual,2020-03-01,NA,Interventional,NA,,A Pilot Study of Sildenafil in COVID-19,A Pilot Study of Sildenafi in the Treatment of COVID-19,Recruiting,NA,Phase 3,10,Anticipated,Tongji Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-24T08:56:07Z,2020-03-24T08:56:07Z,Drug,Sildenafil citrate tablets,0.1g/day for 14 days,1,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04273763,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-14,NA,NA,2020-03-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Estimate,"February 16, 2020",Actual,2020-02-16,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 15, 2020",Anticipated,2020-04-15,NA,Interventional,NA,,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Enrolling by invitation,NA,N/A,60,Anticipated,Second Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:57:21Z,2020-03-24T08:57:21Z,Drug|Drug|Drug,Bromhexine Hydrochloride Tablets|Arbidol Hydrochloride Granules|Recombinant Human Interferon Î±2b Spray,Bromhexine Hydrochloride Tablets|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.,3,,The Second AffIliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,325000,China,1
NCT04293887,"ClinicalTrials.gov processed this data on March 13, 2020",2020-02-15,NA,NA,2020-03-02,2020-03-02,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-02,2020-03-03,Actual,"March 1, 2020",Anticipated,2020-03-01,March 2020,2020-03-31,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,Efficacy and Safety of IFN-Î±2Î² in the Treatment of Novel Coronavirus Patients,"Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon Î±1Î² in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan",Not yet recruiting,NA,Early Phase 1,328,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-14T09:29:16Z,2020-03-14T09:29:16Z,Drug,Recombinant human interferon Î±1Î²,Saline needle 2ml + recombinant human interferon Î±1Î²10ug bid nebulization inhalation,1,NA,NA,NA,NA,NA,NA,NA
NCT04273321,"ClinicalTrials.gov processed this data on March 05, 2020",2020-02-15,NA,NA,2020-02-20,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-24,Actual,"February 14, 2020",Actual,2020-02-14,February 2020,2020-02-29,"May 30, 2020",Anticipated,2020-05-30,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,Efficacy and Safety of Corticosteroids in COVID-19,Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails,Recruiting,NA,N/A,400,Anticipated,Beijing Chao Yang Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-03-06T05:31:45Z,2020-03-06T05:31:45Z,Drug,Methylprednisolone,Methylprednisolone 1mg/kg/day ivgtt for 7 days.,1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Hubei province hospital of integrated Chinese & Western Medicine|Yichang first people's Hospital|Renmin Hospital of Wuhan University|Tianyou Hospital Affiliated to Wuhan University of science and technology|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology,Wuhan|Yichang|Wuhan|Wuhan|Wuhan,Hubei|Hubei|||,||||,China|China|China|China|China,5
NCT04279197,"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-15,NA,NA,2020-02-19,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 15, 2020",Anticipated,2020-02-15,February 2020,2020-02-29,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,NA,,Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu,"A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV",Recruiting,NA,Phase 2,136,Anticipated,ShuGuang Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-03T05:08:01Z,2020-03-03T05:08:01Z,Drug|Drug,N-acetylcysteine+ Fuzheng Huayu Tablet|N-acetylcysteine+Placebo,The subjects will be taking 1 N-acetylcysteine capcule and 4 Fuzheng Huayu tablets three times a day for 24 weeks.|The subjects will be taking 1 N-acetylcysteine capcule and 4 Placebo tablets three times a day for 24 weeks.,2,Recruiting,Shuguang Hospital,Shanghai,Shanghai,201203,China,1
NCT04276987,"ClinicalTrials.gov processed this data on March 06, 2020",2020-02-16,NA,NA,2020-02-21,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 15, 2020",Anticipated,2020-02-15,February 2020,2020-02-29,"July 31, 2020",Anticipated,2020-07-31,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Not yet recruiting,NA,Phase 1,30,Anticipated,Ruijin Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Starting 6 months after publication,NA,NA,Yes,all IPD that underlie results in a publication,2020-03-07T05:30:17Z,2020-03-07T05:30:17Z,Biological,MSCs-derived exosomes,"5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).",1,NA,NA,NA,NA,NA,NA,NA
NCT04275388,"ClinicalTrials.gov processed this data on February 28, 2020",2020-02-17,NA,NA,2020-02-18,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-18,2020-02-19,Actual,"February 14, 2020",Anticipated,2020-02-14,February 2020,2020-02-29,"December 14, 2021",Anticipated,2021-12-14,"May 14, 2020",Anticipated,2020-05-14,NA,Interventional,NA,,Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia,"A Prospective, Randomized, Open, Parallel Controlled, Multicenter Clinical Study of Xiyanping Injection in Combination With Conventional Treatment for the Evaluation of the Effectiveness and Safety of Novel Coronavirus Infection Pneumonia",Not yet recruiting,NA,N/A,348,Anticipated,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-01T00:05:07Z,2020-03-01T00:05:07Z,Drug|Drug,"Xiyanping injection|Lopinavir / ritonavir, alpha-interferon nebulization","Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization",2,NA,NA,NA,NA,NA,NA,NA
NCT04276896,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-17,NA,NA,2020-03-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 24, 2020",Anticipated,2020-03-24,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:57:12Z,2020-03-24T08:57:12Z,Biological,Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs,"Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.",1,Recruiting|Recruiting|Recruiting,Shenzhen Geno-immune Medical Institute|Shenzhen Second People's Hospital|Shenzhen Third People's Hospital,Shenzhen|Shenzhen|Shenzhen,Guangdong|Guangdong|Guangdong,518000|518000|518000,China|China|China,3
NCT04278963,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-19,NA,NA,2020-03-15,2020-02-19,2020-02-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,"February 27, 2020",Actual,2020-02-27,March 2020,2020-03-31,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19,"Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19","Active, not recruiting",NA,Phase 2/Phase 3,300,Anticipated,China Academy of Chinese Medical Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-24T08:57:07Z,2020-03-24T08:57:07Z,Drug|Drug|Other|Other,YinHu QingWen Decoction|YinHu QingWen Decoction(low dose)|Chinese medicine treatment|standard western medicine treatment,"YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.|This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.|This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.|Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.",4,||,Jingzhou Hospital of Traditional Chinese Medicine|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University|Xiangyang Hospital of Traditional Chinese Medicine,Jingzhou|Wuhan|Xiangyang,Hubei|Hubei|Hubei,434000|430200|441000,China|China|China,3
NCT04285190,"ClinicalTrials.gov processed this data on March 06, 2020",2020-02-19,NA,NA,2020-02-24,2020-02-24,2020-02-26,Actual,NA,NA,NA,NA,NA,NA,2020-02-24,2020-02-26,Actual,"February 26, 2020",Anticipated,2020-02-26,February 2020,2020-02-29,"September 15, 2020",Anticipated,2020-09-15,"June 15, 2020",Anticipated,2020-06-15,NA,Interventional,NA,,The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19,A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,NA,N/A,120,Anticipated,"Tasly Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No plan to share,2020-03-08T05:19:27Z,2020-03-08T05:19:27Z,Drug,T89,"The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.",1,NA,NA,NA,NA,NA,NA,NA
NCT04281693,"ClinicalTrials.gov processed this data on March 05, 2020",2020-02-20,NA,NA,2020-02-21,2020-02-21,2020-02-24,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-24,Actual,February 2020,Anticipated,2020-02-29,February 2020,2020-02-29,March 2020,Anticipated,2020-03-31,March 2020,Anticipated,2020-03-31,NA,Interventional,NA,,A New Screening Strategy for 2019 Novel Coronavirus Infection,Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection,Not yet recruiting,NA,N/A,230,Anticipated,Affiliated Hospital to Academy of Military Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-06T05:30:36Z,2020-03-06T05:30:36Z,Diagnostic Test|Diagnostic Test,Standard screening strategy|New screening strategy,The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.,2,,the Fifth Medical Center of Chinese PLA General Hospital,Beijing,Beijing,100071,China,1
NCT04280588,"ClinicalTrials.gov processed this data on March 02, 2020",2020-02-20,NA,NA,2020-02-20,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-21,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Fingolimod in COVID-19,Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19),Recruiting,NA,Phase 2,30,Anticipated,First Affiliated Hospital of Fujian Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-03-03T05:07:12Z,2020-03-03T05:07:12Z,Drug,Fingolimod 0.5 mg,"Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days",1,Recruiting,Wan-Jin Chen,Fuzhou,,,China,1
NCT04280705,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-20,NA,NA,2020-03-19,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Estimate,"February 21, 2020",Actual,2020-02-21,"February 20, 2020",2020-02-20,"April 1, 2023",Anticipated,2023-04-01,"April 1, 2023",Anticipated,2023-04-01,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial,"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 2,394,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-24T08:57:04Z,2020-03-24T08:57:04Z,Other|Drug,Placebo|Remdesivir,"The supplied matching placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients.|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.",2,Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting,"University of California San Diego Health - Jacobs Medical Center|University of California Irvine Medical Center - Infectious Disease|University of California Davis Medical Center - Internal Medicine - Infectious Disease|Emory Vaccine Center - The Hope Clinic|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore|Johns Hopkins Hospital - Medicine - Infectious Diseases|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine|Saint Louis University - Center for Vaccine Development|University of Nebraska Medical Center - Infectious Diseases|Montefiore Medical Center - Infectious Diseases|University of Texas Medical Branch - Division of Infectious Disease|Baylor College of Medicine - Molecular Virology and Microbiology|EvergreenHealth Infectious Disease Service|The University of Washington - Virology Research Clinic|Providence Sacred Heart Medical Center|Seoul National University Bundang Hospital - Division of Infectious Diseases|Seoul National University Hospital|National Centre for Infectious Diseases (NCID)",La Jolla|Orange|Sacramento|Decatur|Annapolis|Baltimore|Bethesda|Minneapolis|Saint Louis|Omaha|Bronx|Galveston|Houston|Kirkland|Seattle|Spokane|Bundang-gu Seongnam-si|Seoul|Singapore,California|California|California|Georgia|Maryland|Maryland|Maryland|Minnesota|Missouri|Nebraska|New York|Texas|Texas|Washington|Washington|Washington|Gyeonggi-do|Jongno-gu|,29037|92868-3298|95817-1460|30030-1705|21401-1527|21287-0005|20892-1504|55455-0341|63104-1015|68198-5400|10467-2401|77555-0435|77030-3411|98034|98104-2433|99204|13620|03080|308442,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Korea, Republic of|Korea, Republic of|Singapore",19
NCT04287686,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-21,NA,NA,2020-03-15,2020-02-25,2020-02-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,February 2020,Anticipated,2020-02-29,March 2020,2020-03-31,April 2020,Anticipated,2020-04-30,April 2020,Anticipated,2020-04-30,NA,Interventional,NA,,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,"A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19",Withdrawn,NA,N/A,0,Actual,The First Affiliated Hospital of Guangzhou Medical University,,2,NA,Without CDE Approval,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-24T08:56:48Z,2020-03-24T08:56:48Z,Drug,Recombinant human angiotensin-converting enzyme 2 (rhACE2),"In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.",1,,GCP Office of The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,510120,China,1
NCT04283461,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-21,NA,NA,2020-03-19,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,"March 3, 2020",Actual,2020-03-03,"February 20, 2020",2020-02-20,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection,"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults",Recruiting,NA,Phase 1,45,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,3,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-24T08:56:55Z,2020-03-24T08:56:55Z,Biological,mRNA-1273,"Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.",1,Not yet recruiting|Recruiting,Emory Children's Center - Pediatric Infectious Diseases|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases,Decatur|Seattle,Georgia|Washington,30030-1705|98101-1466,United States|United States,2
NCT04283838,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-22,NA,NA,2020-03-14,2020-02-22,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"May 15, 2020",Anticipated,2020-05-15,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Humanistic Care in Healthcare Workers in Coronavirus Disease 2019,The Effect of Humanistic Care in Healthcare Workers Participated in the Treatment of Coronavirus Disease 2019,Withdrawn,NA,N/A,0,Actual,Second Affiliated Hospital of Xi'an Jiaotong University,,1,NA,We cannot enroll enough participants.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:56:54Z,2020-03-24T08:56:54Z,Behavioral,Humanistic Care,Psychological and physical rehabilitation based humanistic care regimen,1,NA,NA,NA,NA,NA,NA,NA
NCT04283825,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-22,NA,NA,2020-03-14,2020-02-22,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"May 15, 2020",Anticipated,2020-05-15,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Humanistic Care in Patients With Coronavirus Disease 2019,The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With Coronavirus Disease 2019,Withdrawn,NA,N/A,0,Actual,Second Affiliated Hospital of Xi'an Jiaotong University,,2,NA,We cannot enroll enough participants.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:56:54Z,2020-03-24T08:56:54Z,Behavioral,Psychological and physical rehabilitation based humanistic care,"This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.",1,NA,NA,NA,NA,NA,NA,NA
NCT04303299,"ClinicalTrials.gov processed this data on March 20, 2020",2020-02-24,NA,NA,2020-03-10,2020-03-08,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-10,2020-03-12,Actual,"March 15, 2020",Anticipated,2020-03-15,March 2020,2020-03-31,"November 30, 2020",Anticipated,2020-11-30,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,THDMS-COVID19,,"Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial","A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Chloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Chloroquine in Mild COVID19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Chloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Chloroquine in Moderate to Critically Ill COVID19",Not yet recruiting,NA,Phase 3,80,Anticipated,Rajavithi Hospital,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-03-22T09:04:34Z,2020-03-22T09:04:34Z,Drug,Oral,Anti virus treatment,1,,Assistant Professor Subsai Kongsaengdao,Bangkok,,10400,Thailand,1
NCT04293692,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-24,NA,NA,2020-03-15,2020-02-29,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-18,Actual,"February 24, 2020",Actual,2020-02-24,March 2020,2020-03-31,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus,Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus,Withdrawn,NA,N/A,0,Actual,Puren Hospital Affiliated to Wuhan University of Science and Technology,,2,NA,"Patients were transferred to designated hospitals for treatment as needed, the clinical trials
    cannot be conducted.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-24T08:56:33Z,2020-03-24T08:56:33Z,Biological|Other,UC-MSCs|Placebo,"0.5*10E6 UC-MSCs /kg body weight suspended in 100mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7|100mL saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7",2,,Puren Hospital Affiliated to Wuhan University of Science and Technology,Wuhan,Hubei,430081,China,1
NCT04288102,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-24,NA,NA,2020-03-19,2020-02-25,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Estimate,"March 5, 2020",Actual,2020-03-05,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19),"Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Mesenchymal Stem Cell(MSC) for the Treatment of Severe Corona Virus Disease 2019(COVID-19)",Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:56:46Z,2020-03-24T08:56:46Z,Biological|Biological,MSCs|Saline containing 1% Human serum albuminï¼ˆsolution of MSCï¼‰,"3 times of MSCs(4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.|3 times of placeboï¼ˆintravenously at Day 0, Day 3, Day 6ï¼‰",2,Recruiting|Recruiting,Maternal and Child Hospital of Hubei Province|Wuhan Huoshenshan Hospital,Wuhan|Wuhan,Hubei|Hubei,430000|430000,China|China,2
NCT04286503,"ClinicalTrials.gov processed this data on March 06, 2020",2020-02-25,NA,NA,2020-02-25,2020-02-25,2020-02-27,Actual,NA,NA,NA,NA,NA,NA,2020-02-25,2020-02-27,Actual,"February 23, 2020",Anticipated,2020-02-23,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,NA,,The Clinical Study of Carrimycin on Treatment Patients With COVID-19,"The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study",Not yet recruiting,NA,Phase 4,520,Anticipated,Beijing YouAn Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-09T09:10:50Z,2020-03-09T09:10:50Z,Drug|Drug|Drug,Carrimycin|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|basic treatment,Carrimycin|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|basic treatment,3,NA,NA,NA,NA,NA,NA,NA
NCT04291729,"ClinicalTrials.gov processed this data on March 16, 2020",2020-02-27,NA,NA,2020-03-04,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-04,2020-03-06,Actual,"February 17, 2020",Actual,2020-02-17,February 2020,2020-02-29,"April 30, 2020",Anticipated,2020-04-30,"March 31, 2020",Anticipated,2020-03-31,NA,Interventional,NA,,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of Novel Coronavirus Infection,An Open and Controlled Clinical Trial to Evaluate Ganovoï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of Novel Coronavirusï¼ˆ2019-nCoVï¼‰ Infection,Recruiting,NA,Phase 4,50,Anticipated,The Ninth Hospital of Nanchang,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-17T09:07:01Z,2020-03-17T09:07:01Z,Drug|Drug|Drug|Drug|Drug,Ganovo+ritonavir+/-Interferon atomization|Long acting interferon|Recombinant cytokine gene-derived protein|Lopinavir+ritonavir|Chinese medicines +interferon atomization,"Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50Î¼g / time for adults, twice a day up to 14 days.|Pegasys 180 Î¼g, subcutaneous injection once a week.|Spray inhalation of Novaferon, 20 Î¼g, twice a day, up to 14 days.|Lopinavir/ritonavir, 200 mg / 50 mg, per tablet, oral, 2 tablets at a time, twice a day, up to 14 days.|Chinese medicines , up to 14 days.Spray inhalation of interferon, 50Î¼g / time for adults, twice a day up to 14 days.",5,Recruiting,The Ninth Hospital of Nanchang,Nanchang,Jiangxi,330000,China,1
NCT04290871,"ClinicalTrials.gov processed this data on March 16, 2020",2020-02-27,NA,NA,2020-03-03,2020-02-27,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-06,Actual,"March 1, 2020",Anticipated,2020-03-01,March 2020,2020-03-31,"March 1, 2022",Anticipated,2022-03-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,NOSARSCOVID,,Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.,Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.,Not yet recruiting,NA,Phase 2,104,Anticipated,Xijing Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-17T09:07:06Z,2020-03-17T09:07:06Z,Drug,Nitric Oxide Gas,"Inspired NO will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment. After that, NO levels will be decreased to 40 ppm until severe hypoxia resolves. Weaning from NO will start when patients improves the level of oxygenation to a PaO2/FiO2 > 300 mmHg or SpO2 > 93% for more than 24 hours consecutively. Physician will follow their own institutional weaning protocols. In the absence of institutional protocols, NO will be reduced every 4 hours in step-wise fashion starting from 40 ppm to 20, 10, 5, 3, 2 and 1 ppm.",1,NA,NA,NA,NA,NA,NA,NA
NCT04302519,"ClinicalTrials.gov processed this data on March 19, 2020",2020-02-27,NA,NA,2020-03-09,2020-03-09,2020-03-10,Actual,NA,NA,NA,NA,NA,NA,2020-03-09,2020-03-10,Actual,"March 5, 2020",Anticipated,2020-03-05,February 2020,2020-02-29,"July 30, 2021",Anticipated,2021-07-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells,Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells,Not yet recruiting,NA,Early Phase 1,24,Anticipated,"CAR-T (Shanghai) Biotechnology Co., Ltd.",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-20T09:16:55Z,2020-03-20T09:16:55Z,Biological,Dental pulp mesenchymal stem cells,"On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.",1,NA,NA,NA,NA,NA,NA,NA
NCT04290858,"ClinicalTrials.gov processed this data on March 20, 2020",2020-02-27,NA,NA,2020-03-09,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-09,2020-03-11,Actual,"March 1, 2020",Anticipated,2020-03-01,March 2020,2020-03-31,"February 1, 2022",Anticipated,2022-02-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,NoCovid,,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial,Not yet recruiting,NA,Phase 2,240,Anticipated,Xijing Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-21T09:13:51Z,2020-03-21T09:13:51Z,Drug,Nitric Oxide,"Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.",1,NA,NA,NA,NA,NA,NA,NA
NCT04291053,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-27,NA,NA,2020-03-14,2020-02-27,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"September 1, 2020",Anticipated,2020-09-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19,"The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study",Not yet recruiting,NA,Phase 2/Phase 3,550,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-24T08:56:41Z,2020-03-24T08:56:41Z,Drug,Huaier Granule,standard treatment + Huaier Granule 20g po tid for 2weeks,1,NA,NA,NA,NA,NA,NA,NA
NCT04299152,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-28,NA,NA,2020-03-19,2020-03-05,2020-03-06,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,"April 10, 2020",Anticipated,2020-04-10,March 2020,2020-03-31,"November 10, 2020",Anticipated,2020-11-10,"October 9, 2020",Anticipated,2020-10-09,NA,Interventional,NA,,Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2,Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Not yet recruiting,NA,Phase 2,20,Anticipated,Tianhe Stem Cell Biotechnologies Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:56:25Z,2020-03-24T08:56:25Z,Combination Product,Stem Cell Educator-Treated Mononuclear Cells Apheresis,"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the ""educated"" autologous immune cells to the patient's circulation.",1,NA,NA,NA,NA,NA,NA,NA
NCT04292899,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-28,NA,NA,2020-03-20,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-20,2020-03-23,Estimate,"March 6, 2020",Actual,2020-03-06,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,Recruiting,NA,Phase 3,400,Anticipated,Gilead Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:56:38Z,2020-03-24T08:56:38Z,Drug|Drug,Remdesivir|Standard of Care,Administered as an intravenous infusion|Standard of care therapy per local written policies or guidelines,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Hoag Memorial Hospital Presbyterian|Stanford Hospital|University of Chicago|Brigham & Women's Hospital and Harvard Medical School|The Miriam Hospital|Providence Regional Medical Center Everett|Swedish Center for Comprehensive Care|Prince of Wales Hospital|Princess Margaret Hospital|Queen Mary Hospital|Kyungpook National University Hospital|Seoul Medical Center|National Medical Center|National University Hospital|Singapore General Hospital|National Centre for Infectious Diseases, Tan Tock Seng Hospital|National Taiwan University Hospital",Newport Beach|Stanford|Chicago|Boston|Providence|Everett|Seattle|Hong Kong|Hong Kong|Hong Kong|Daegu|Seoul|Seoul|Singapore|Singapore|Singapore|Taipei City,California|California|Illinois|Massachusetts|Rhode Island|Washington|Washington||||||||||,92658|94305|60637|02115|02906|98201|98104||||41944|02053|04564|119228|169856|308442|10002,"United States|United States|United States|United States|United States|United States|United States|Hong Kong|Hong Kong|Hong Kong|Korea, Republic of|Korea, Republic of|Korea, Republic of|Singapore|Singapore|Singapore|Taiwan",17
NCT04292730,"ClinicalTrials.gov processed this data on March 23, 2020",2020-02-28,NA,NA,2020-03-20,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-20,2020-03-23,Estimate,"March 15, 2020",Actual,2020-03-15,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,Recruiting,NA,Phase 3,600,Anticipated,Gilead Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:56:39Z,2020-03-24T08:56:39Z,Drug|Drug,Remdesivir|Standard of Care,Administered as an intravenous infusion|Standard of care therapy per local written policies or guidelines,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Hoag Memorial Hospital Presbyterian|Stanford Hospital|University of Chicago|Brigham & Women's Hospital and Harvard Medical School|The Miriam Hospital|Providence Medical Research Center|Swedish Center for Comprehensive Care|Prince of Wales Hospital|Princess Margaret Hospital|Queen Mary Hospital|Kyungpook National University Hospital|Seoul Medical Center|National Medical Center|National University Hospital|Singapore General Hospital|National Centre for Infectious Diseases, Tan Tock Seng Hospital|National Taiwan University Hospital",Newport Beach|Stanford|Chicago|Boston|Providence|Everett|Seattle|Hong Kong|Hong Kong|Hong Kong|Daegu|Seoul|Seoul|Singapore|Singapore|Singapore|Taipei City,California|California|Illinois|Massachusetts|Rhode Island|Washington|Washington||||||||||,92658|94305|60637|02115|02906|98201|98104||||41944|02053|04564|119228|169856|308442|10002,"United States|United States|United States|United States|United States|United States|United States|Hong Kong|Hong Kong|Hong Kong|Korea, Republic of|Korea, Republic of|Korea, Republic of|Singapore|Singapore|Singapore|Taiwan",17
NCT04295551,"ClinicalTrials.gov processed this data on March 13, 2020",2020-03-03,NA,NA,2020-03-03,2020-03-03,2020-03-04,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-04,Actual,"March 14, 2020",Anticipated,2020-03-14,March 2020,2020-03-31,"April 14, 2021",Anticipated,2021-04-14,"July 14, 2020",Anticipated,2020-07-14,NA,Interventional,NA,,Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe),Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe),Not yet recruiting,NA,N/A,80,Anticipated,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-15T09:18:57Z,2020-03-15T09:18:57Z,Drug|Drug,Lopinavir / ritonavir tablets combined with Xiyanping injection|Lopinavir/ritonavir treatment,"Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization",2,NA,NA,NA,NA,NA,NA,NA
NCT04296643,"ClinicalTrials.gov processed this data on March 13, 2020",2020-03-03,NA,NA,2020-03-03,2020-03-03,2020-03-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-05,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"January 1, 2021",Anticipated,2021-01-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Medical Masks vs N95 Respirators for COVID-19,Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial,Not yet recruiting,NA,N/A,576,Anticipated,McMaster University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-16T09:09:15Z,2020-03-16T09:09:15Z,Device|Device,Medical Mask|N95 respirator,Medical Mask (known also as Surgical Mask)|N95 respirator,2,NA,NA,NA,NA,NA,NA,NA
NCT04308317,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-04,NA,NA,2020-03-13,2020-03-13,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-16,Actual,"March 5, 2020",Anticipated,2020-03-05,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,TT-NPC,,Tetrandrine Tablets Used in the Treatment of COVID-19,Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19,Enrolling by invitation,NA,Phase 4,60,Anticipated,Henan Provincial People's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:55:37Z,2020-03-24T08:55:37Z,Drug,Tetrandrine,Tetrandrine 60mg QD for 1week,1,,Tetrandrine Tablets,Jinhua,Zhejiang,321000,China,1
NCT04299724,"ClinicalTrials.gov processed this data on March 18, 2020",2020-03-05,NA,NA,2020-03-06,2020-03-06,2020-03-09,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-09,Actual,"February 15, 2020",Actual,2020-02-15,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,NA,Phase 1,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-19T09:19:21Z,2020-03-19T09:19:21Z,Biological,Pathogen-specific aAPC,The subjects will receive three injections of 5x10^6 each Covid-19/aAPC vaccine via subcutaneous injections.,1,Recruiting,Shenzhen Geno-immune Medical Institute,Shenzhen,Guangdong,518000,China,1
NCT04304053,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-05,NA,NA,2020-03-13,2020-03-07,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-17,Actual,"March 15, 2020",Anticipated,2020-03-15,March 2020,2020-03-31,"July 15, 2020",Anticipated,2020-07-15,"July 15, 2020",Anticipated,2020-07-15,NA,Interventional,HCQ4COV19,,Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic,Antiviral Treatment of COVID-19 Confirmed Cases and Ring Chloroquine Chemoprevention in Close Contacts: a Cluster Randomized Clinical Trial,Not yet recruiting,NA,Phase 3,3040,Anticipated,Lihir Medical Centre,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:56:08Z,2020-03-24T08:56:08Z,Drug|Other,Antiviral treatment and prophylaxis|Standard Public Health measures,"darunavir 800 mg / cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2,3,4.
Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2,3,4.|Isolation of patient and contact tracing as per national guidelines.",2,NA,NA,NA,NA,NA,NA,NA
NCT04303507,"ClinicalTrials.gov processed this data on March 20, 2020",2020-03-06,NA,NA,2020-03-10,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-10,2020-03-11,Actual,May 2020,Anticipated,2020-05-31,March 2020,2020-03-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,COPCOV,,Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,"Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)",Not yet recruiting,NA,N/A,10000,Anticipated,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing,Yes,"With participant's consent, suitably anonymised clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.",2020-03-21T09:12:41Z,2020-03-21T09:12:41Z,Drug|Drug,Chloroquine|Placebo,A loading dose of 10 mg base/ kg followed by 150 mg daily (250mg chloroquine phosphate salt) will be taken for 3 months|Placebo,2,NA,NA,NA,NA,NA,NA,NA
NCT04306055,"ClinicalTrials.gov processed this data on March 20, 2020",2020-03-08,NA,NA,2020-03-10,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-10,2020-03-12,Actual,"March 12, 2020",Anticipated,2020-03-12,March 2020,2020-03-31,"April 9, 2020",Anticipated,2020-04-09,"March 19, 2020",Anticipated,2020-03-19,NA,Interventional,NA,,Blood Donor Recruitment During Epidemic of COVID-19,"Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China",Not yet recruiting,NA,N/A,1500,Anticipated,Guangzhou Blood Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-22T09:03:37Z,2020-03-22T09:03:37Z,Other|Other,Questionnaire with precaution information|Experimental: Questionnaire without precaution information,Ever blood donors in this group would receive a questionnaire which includes some information about how donors can donate safely and how blood center will protect the blood donors during the epidemic of COVID-19.|Ever blood donors in this group would receive a questionnaire which dose not include the information above.,2,NA,NA,NA,NA,NA,NA,NA
NCT04305106,"ClinicalTrials.gov processed this data on March 20, 2020",2020-03-09,NA,NA,2020-03-09,2020-03-09,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-09,2020-03-12,Actual,"March 12, 2020",Anticipated,2020-03-12,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia-RCT,The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia--a Multi-Centered Randomized ControlledClinical Trial,Not yet recruiting,NA,N/A,118,Anticipated,Qilu Hospital of Shandong University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-22T09:04:11Z,2020-03-22T09:04:11Z,Drug,Bevacizumab,"Bevacizumab 500mg + 0.9% NaCl 100ml, intravenous drip",1,,Qilu Hospital of Shandong University,Jinan,Shandong,250012,China,1
NCT04305457,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-09,NA,NA,2020-03-17,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 13, 2020",Anticipated,2020-03-13,March 2020,2020-03-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NoCovid,,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial,Not yet recruiting,NA,Phase 2,240,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-24T08:55:59Z,2020-03-24T08:55:59Z,Drug,Nitric Oxide,"Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the patient.",1,NA,NA,NA,NA,NA,NA,NA
NCT04304690,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-09,NA,NA,2020-03-17,2020-03-09,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 16, 2020",Actual,2020-03-16,March 2020,2020-03-31,"October 16, 2020",Anticipated,2020-10-16,"July 16, 2020",Anticipated,2020-07-16,NA,Interventional,SEROCOV,,"Sars-CoV2 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Sars-CoV2 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic",Recruiting,NA,N/A,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:56:04Z,2020-03-24T08:56:04Z,Other,blood sample,2 blood samples at T0 and 3 months,1,Recruiting,Hopital PitiÃ© SalpetriÃ¨re,Paris,,75013,France,1
NCT04307693,"ClinicalTrials.gov processed this data on March 20, 2020",2020-03-10,NA,NA,2020-03-12,2020-03-12,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-03-12,2020-03-13,Actual,"March 11, 2020",Actual,2020-03-11,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Recruiting,NA,Phase 2,150,Anticipated,Asan Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-23T08:53:53Z,2020-03-23T08:53:53Z,Drug|Drug,Lopinavir/ritonavir|Hydroxychloroquine sulfate,Lopinavir / Ritonavir tablet|Hydroxychloroquine sulfate tablet,2,Recruiting,"Asan Medical Center, University of Ulsan College of Medicine",Seoul,,138-736,"Korea, Republic of",1
NCT04306393,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-10,NA,NA,2020-03-16,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-18,Actual,"March 10, 2020",Anticipated,2020-03-10,March 2020,2020-03-31,"March 10, 2022",Anticipated,2022-03-10,"March 10, 2021",Anticipated,2021-03-10,NA,Interventional,NOSARSCOVID,,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.,Not yet recruiting,NA,Phase 2,200,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-24T08:55:54Z,2020-03-24T08:55:54Z,Drug,Nitric Oxide Gas,"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.
Weaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively.",1,NA,NA,NA,NA,NA,NA,NA
NCT04308668,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-11,NA,NA,2020-03-19,2020-03-11,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Estimate,"March 17, 2020",Anticipated,2020-03-17,March 2020,2020-03-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Post-exposure Prophylaxis for SARS-Coronavirus-2,Post-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Recruiting,NA,Phase 2/Phase 3,1500,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:55:24Z,2020-03-24T08:55:24Z,Drug|Other,Hydroxychloroquine|Placebo,"200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days",2,Recruiting,University of Minnesota,Minneapolis,Minnesota,55455,United States,1
NCT04316377,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-13,NA,NA,2020-03-18,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-20,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"March 3, 2025",Anticipated,2025-03-03,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NO COVID-19,,Norwegian Coronavirus Disease 2019 Study,Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection,Not yet recruiting,NA,Phase 4,202,Anticipated,"University Hospital, Akershus",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-03-24T08:50:47Z,2020-03-24T08:50:47Z,Drug,Hydroxychloroquine Sulfate,400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days,1,NA,NA,NA,NA,NA,NA,NA
NCT04315948,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-13,NA,NA,2020-03-18,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-20,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,DisCoVeRy,,Trial of Treatments for COVID-19 in Hospitalized Adults,"Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults",Not yet recruiting,NA,Phase 3,3200,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-24T08:51:02Z,2020-03-24T08:51:02Z,Drug|Drug|Drug|Other,Remdesivir|Lopinavir/ritonavir|Interferon Beta-1A|Standard of care,"The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 150 mg of Remdesivir to be reconstituted with 29 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 30 mL (150 mg of Remdesivir). It is supplied as a sterile product in a single-use, 50 mL, Type 1 clear glass vial.|The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the ""a"" logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL).|IFN-ÃŸ-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 Âµg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.|Standard of care.",4,NA,NA,NA,NA,NA,NA,NA
NCT04312009,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-13,NA,NA,2020-03-19,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Estimate,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Not yet recruiting,NA,Phase 2,200,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-24T08:53:19Z,2020-03-24T08:53:19Z,Drug|Other,Losartan|Placebo,"Losartan; 25 mg daily; oral administration|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration",2,||,Hennepin County Medical Center|M Health Fairview University of Minnesota Medical Center|University of Minnesota,Minneapolis|Minneapolis|Minneapolis,Minnesota|Minnesota|Minnesota,55415|55455|55455,United States|United States|United States,3
NCT04311177,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-13,NA,NA,2020-03-19,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Estimate,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Not yet recruiting,NA,Phase 2,516,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-24T08:53:53Z,2020-03-24T08:53:53Z,Drug|Other,Losartan|Placebo,"Losartan; 25 mg daily; oral administration|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration",2,||,Hennepin County Medical Center|M Health Fairview University of Minnesota Medical Center|University of Minnesota,Minneapolis|Minneapolis|Minneapolis,Minnesota|Minnesota|Minnesota,55415|55455|55455,United States|United States|United States,3
NCT04316728,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-14,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Clinical Performance of the VivaDiag â„¢ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19,Clinical Performance of the VivaDiag â„¢ COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19,Not yet recruiting,NA,N/A,200,Anticipated,"Centro Studi Internazionali, Italy",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,12 months,Still under development,NA,Yes,Still under development,2020-03-24T08:50:35Z,2020-03-24T08:50:35Z,Device,VivaDiagâ„¢ COVID-19 lgM/IgG Rapid Test,"VivaDiagâ„¢ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma",1,,"UnitÃ ' Complesse di cure primarie (UCCP), ASP Catanzaro",Catanzaro,,88100,Italy,1
NCT04315480,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-14,NA,NA,2020-03-18,2020-03-18,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-19,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,April 2020,Anticipated,2020-04-30,NA,Interventional,NA,,Tocilizumab for SARS-CoV2 Severe Pneumonitis,Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 Infection With Severe Multifocal Interstitial Pneumonia,Not yet recruiting,NA,Phase 2,30,Anticipated,UniversitÃ  Politecnica delle Marche,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-24T08:51:17Z,2020-03-24T08:51:17Z,Drug,Tocilizumab,single intravenous administration 8mg/Kg,1,,UniversitÃ  Politecnica delle Marche,Ancona,AN,60020,Italy,1
NCT04311697,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-14,NA,NA,2020-03-16,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-18,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,COVID-AIV,,Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress,Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress,Not yet recruiting,NA,Phase 2,20,Anticipated,"NeuroRx, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-03-24T08:53:33Z,2020-03-24T08:53:33Z,Drug|Drug,Aviptadil by intravenous infusion|Aviptadil by endotracheal nebulization,Aviptadil by intravenous infusion|Aviptadil by endotracheal nebulization,2,|,Research Facility|Rambam Health Care Campus,New York|Haifa,New York|,10016|3109601,United States|Israel,2
NCT04315298,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-15,NA,NA,2020-03-17,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 16, 2020",Actual,2020-03-16,March 2020,2020-03-31,"March 16, 2021",Anticipated,2021-03-16,"March 16, 2021",Anticipated,2021-03-16,NA,Interventional,NA,,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2/Phase 3,400,Anticipated,Regeneron Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://errs.regeneron.com/external,Yes,All IPD that underlie publicly available results will be considered for sharing,2020-03-24T08:51:24Z,2020-03-24T08:51:24Z,Drug|Drug,Sarilumab|Placebo,Single intravenous (IV) dose of sarilumab|Single intravenous (IV) dose of placebo to match sarilumab administration,2,Recruiting,Regeneron Study Site,New York,New York,10029,United States,1
NCT04313322,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-15,NA,NA,2020-03-15,2020-03-15,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-18,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,NA,Phase 1,5,Anticipated,Stem Cells Arabia,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:52:32Z,2020-03-24T08:52:32Z,Biological,WJ-MSCs,"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.
WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.",1,Recruiting,Stem Cells Arabia,Amman,,11953,Jordan,1
NCT04313127,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-15,NA,NA,2020-03-17,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-18,Actual,"March 19, 2020",Anticipated,2020-03-19,March 2020,2020-03-31,"December 20, 2022",Anticipated,2022-12-20,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,PICTHA,,Phase I Clinical Trial in Healthy Adult,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old",Not yet recruiting,NA,Phase 1,108,Anticipated,CanSino Biologics Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:52:39Z,2020-03-24T08:52:39Z,Biological,Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),Intramuscular other name:Ad5-nCoV,1,NA,NA,NA,NA,NA,NA,NA
NCT04312243,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-15,NA,NA,2020-03-16,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-18,Actual,"March 20, 2020",Anticipated,2020-03-20,March 2020,2020-03-31,"March 20, 2022",Anticipated,2022-03-20,"March 20, 2021",Anticipated,2021-03-20,NA,Interventional,NOpreventCOVID,,NO Prevention of COVID-19 for Healthcare Providers,Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers,Not yet recruiting,NA,Phase 2,460,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-03-24T08:53:11Z,2020-03-24T08:53:11Z,Drug,Inhaled nitric oxide gas,"Observational group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.",1,NA,NA,NA,NA,NA,NA,NA
NCT04310865,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-15,NA,NA,2020-03-15,2020-03-15,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,"March 20, 2020",Anticipated,2020-03-20,March 2020,2020-03-31,"June 30, 2021",Anticipated,2021-06-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,,Yinhu Qingwen Granula for the Treatment of Severe CoVID-19,"An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19",Not yet recruiting,NA,Phase 2/Phase 3,116,Anticipated,China Academy of Chinese Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-03-24T08:54:03Z,2020-03-24T08:54:03Z,Drug|Drug|Other,Yinhu Qingwen Granula|Yin Hu Qing Wen Granula(low does)|standard medical treatment,"Yinhu Qingwen Granula is a kind of herbal granula made from ""Yinhu Qingwen Decoction"", which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.|This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).|Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.",3,|||,Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University,Wuhan|Wuhan|Wuhan|Wuhan,Hubei|Hubei|Hubei|Hubei,430071|430071|430071|430200,China|China|China|China,4
NCT04313023,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-16,NA,NA,2020-03-16,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-18,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing COVID-19 Infection in Adults Exposed to COVID-19,Not yet recruiting,NA,Phase 2,200,Anticipated,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:52:43Z,2020-03-24T08:52:43Z,Drug|Drug,PUL-042 Inhalation Solution|Placebo,"20.3 Âµg Pam2 : 29.8 Âµg ODN/mL (50 Âµg PUL-042) PUL-042 Inhalation Solution will be given by nebulization on study days 1, 3, 6, and 10|Sterile normal saline for inhalation",2,NA,NA,NA,NA,NA,NA,NA
NCT04312997,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-16,NA,NA,2020-03-18,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-19,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Not yet recruiting,NA,Phase 2,100,Anticipated,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:52:43Z,2020-03-24T08:52:43Z,Drug|Drug,PUL-042 Inhalation Solution|Placebo,"20.3 Âµg Pam2 : 29.8 Âµg ODN/mL (50 Âµg PUL-042) given by nebulization on study days 1, 3 and 6|Sterile normal saline for inhalation",2,,Houston Methodist Hospital,Houston,Texas,77030,United States,1
NCT04315987,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-18,NA,NA,2020-03-19,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Estimate,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Interventional,HOPE,,NestCellÂ® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,Exploratory Clinical Study to Assess the Efficacy of NestCellÂ® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,Not yet recruiting,NA,Phase 1,24,Anticipated,Azidus Brasil,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.",2020-03-24T08:51:00Z,2020-03-24T08:51:00Z,Biological|Biological,NestCellÂ®|NestCellÂ®,"Phase 1 of the study: 6 patients will receive conventional treatment plus 3 times of 1x10^6 cells /kg body weight of NestCellÂ® intravenously on Day1, Day3 and Day7|Phase 2 of the study: After Safety Monitoring Board evaluation, 18 patients will receive conventional treatment plus the dose and posology of NestCellÂ® recommended by Board.",2,NA,NA,NA,NA,NA,NA,NA
NCT04315896,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-18,NA,NA,2020-03-18,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-20,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"March 22, 2021",Anticipated,2021-03-22,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,HYDRA,,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial),Not yet recruiting,NA,Phase 3,500,Anticipated,"National Institute of Respiratory Diseases, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,As requested by other investigators.,2020-03-24T08:51:03Z,2020-03-24T08:51:03Z,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,hydroxychloroquine 400mg day for 10 days|Placebo oral tablet,2,NA,NA,NA,NA,NA,NA,NA
NCT04318015,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-19,NA,NA,2020-03-19,2020-03-19,2020-03-23,Estimate,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,PHYDRA,,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial),Not yet recruiting,NA,Phase 3,400,Anticipated,"National Institute of Respiratory Diseases, Mexico",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-03-24T08:49:49Z,2020-03-24T08:49:49Z,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,All treatment will be administered orally.|All placebo will be administered orally,2,NA,NA,NA,NA,NA,NA,NA
NCT04317092,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-19,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,"March 19, 2020",Actual,2020-03-19,March 2020,2020-03-31,"December 19, 2022",Anticipated,2022-12-19,"December 19, 2020",Anticipated,2020-12-19,NA,Interventional,TOCIVID-19,,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia,Recruiting,NA,Phase 2,330,Anticipated,"National Cancer Institute, Naples",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:50:24Z,2020-03-24T08:50:24Z,Drug,Tocilizumab Injection,"Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose), with an interval of 12 hours.",1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia)|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive)|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza)|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O.|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive)|ASST OVEST MILANESE presidi Legnano - Magenta|Azienda Ospedaliero-Universitaria di Modena|A.O.U. di Modena (Dipartimento Chirurgie Generali e SpecialitÃ  Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I)|A.O.U. di Modena (Dipartimento Chirurgie Generali e SpecialitÃ  Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II)|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive)|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia)|National Cancer Institute|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva)|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio)|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza)|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione)|Grande Ospedale Metropolitano, Reggio Calabria|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive)|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche)|ASST Sette Laghi (Dipartimento di Medicina Interna)|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze)|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale)|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali)|A.O.U. Integrata di Verona (Dip. Malattie Infettive)|Ospedale Magalini (U.O. Malattie Infettive)",Alessandria|Busto Arsizio|Catania|Catania|Cosenza|Magenta|Modena|Modena|Modena|Modena|Modena|Naples|Naples|Naples|Naples|Pesaro|Pozzuoli|Ravenna|Reggio Calabria|Rimini|Rome|Varese|Varese|Varese|Varese|Verona|Villafranca Di Verona,||||||||||||||||||||||||||,||||||42100|||||80131|80131||||||||||||||,Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy,27
NCT04317040,"ClinicalTrials.gov processed this data on March 23, 2020",2020-03-19,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Estimate,May 2020,Anticipated,2020-05-31,March 2020,2020-03-31,May 2022,Anticipated,2022-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,SAC-COVID,,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Not yet recruiting,NA,Phase 3,230,Anticipated,"OncoImmune, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-03-24T08:50:25Z,2020-03-24T08:50:25Z,Drug|Drug,CD24Fc|Placebo,CD24Fc is given on Day 1.|Placebo is given on Day 1.,2,,"Institute of Human Virology, University of Maryland Baltimore",Baltimore,Maryland,21201,United States,1
